Adaptive vs standard radiation for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial compares two ways of giving radiation to the prostate and pelvic lymph nodes. It also tests two different instructions for how full your bladder should be during treatment. The goal is to see which approach works better and is easier for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of prostate cancer that has not spread to other parts of the body.
- Your cancer is considered intermediate or high risk based on standard tests (like PSA, Gleason score, and tumor stage).
- You are able to have radiation therapy using the specific BC Cancer treatment plan (20 sessions).
- You have good bladder control or can manage it with a clamp or cuff, and you can follow instructions about filling your bladder.
- Your urinary symptoms are mild (IPSS score less than 20).
- You are able to lie still for 30 minutes and have not had radiation to the pelvic area before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
This trial tests a new type of radiation therapy that is customized for each patient's prostate cancer. The radiation targets the tumor more precisely, which may help reduce side effects while treating the cancer effectively.
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.